| AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Am J Translational Res 2011;3(3):251-258
Review Article
Emerging tactical strategies for fighting the war on cancer based on
the genetic landscape
Peter D. Burbelo, Kathryn H. Ching, Kathleen E. Bren, Michael J. Iadarola
Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and
Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
Received March 15, 2011; accepted April 6, 2011; Epub April 8, 2011; Published May 15, 2011
Abstract: Although it is well-established that cancer is driven by genetic mutations resulting in the acquisition of
oncogenes and the loss of tumor suppressors, until recently many of the genomic details remained obscure. As
a result of recent high-throughput DNA sequencing, basic insights into the spectrum of protein coding mutations
in many cancers are now known. These findings provide an unprecedented framework of understanding and
present new avenues for diagnosis, treatment, and prevention of cancer. In this article we discuss several high
impact areas of global sequencing projects including developing drugs that specifically target cancer cells,
creating personalized tools for better treatment and monitoring, and developing pre-symptomatic diagnostic
tests. Capitalizing on these and other advances represent a new turning point in the war on cancer.
(AJTR1103005).
Keywords: Genetic mutations, cancer, diagnosis, therapy, oncogenes, tumor suppressors, high through-put DNA
sequencing, review
Full Text PDF
Address all correspondence to:
Peter D. Burbelo, PhD
Building 49, Room 1C36
49 Convent Drive
Bethesda, MD 20892, USA.
Phone: 301-402-0778. Fax: 301-402-0667
E-mail: burbelop@nidcr.nih.gov
Review Article
Emerging tactical strategies for fighting the war on cancer based on
the genetic landscape
Peter D. Burbelo, Kathryn H. Ching, Kathleen E. Bren, Michael J. Iadarola
Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and
Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
Received March 15, 2011; accepted April 6, 2011; Epub April 8, 2011; Published May 15, 2011
Abstract: Although it is well-established that cancer is driven by genetic mutations resulting in the acquisition of
oncogenes and the loss of tumor suppressors, until recently many of the genomic details remained obscure. As
a result of recent high-throughput DNA sequencing, basic insights into the spectrum of protein coding mutations
in many cancers are now known. These findings provide an unprecedented framework of understanding and
present new avenues for diagnosis, treatment, and prevention of cancer. In this article we discuss several high
impact areas of global sequencing projects including developing drugs that specifically target cancer cells,
creating personalized tools for better treatment and monitoring, and developing pre-symptomatic diagnostic
tests. Capitalizing on these and other advances represent a new turning point in the war on cancer.
(AJTR1103005).
Keywords: Genetic mutations, cancer, diagnosis, therapy, oncogenes, tumor suppressors, high through-put DNA
sequencing, review
Full Text PDF
Address all correspondence to:
Peter D. Burbelo, PhD
Building 49, Room 1C36
49 Convent Drive
Bethesda, MD 20892, USA.
Phone: 301-402-0778. Fax: 301-402-0667
E-mail: burbelop@nidcr.nih.gov
 | |  | |  | |  | |  | |  | |  |